Skip to main content
OPRX logo

OPRX

OptimizeRx Corp
$6.19 +0.11 (+1.81%) At close · Jul 2
Market Cap
$116.16M
Shares
18,765,075

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-06-30 OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest WALTHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences

2026-06-25 OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms

Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts WALTHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology

2026-06-01 OptimizeRx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the

2026-05-21 DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx’s Authenticated EHR Network

Powered by OptimizeRx’s new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers WALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life

2026-05-12 OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

– Q1 revenue totals $19.8 million – Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively – 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million – Paid off an incremental $2.7 million in principal from term loan

2026-05-11 OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale

Expands life sciences marketers’ reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx’s trusted EHR network for the first time WALTHAM, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare

2026-04-29 OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report

WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and

2026-04-28 OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET

WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Tuesday, May 12, 2026, at 4:30

2026-04-08 OptimizeRx Appoints Mary Varghese Presti to Board of Directors

Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions

2026-03-05 UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

-   Q4 revenue of $32.2 million -   Q4 gross profit increased 9% year-over-year to $24.1 million -   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively -   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million

Past events

Source: https://investors.optimizerx.com/

Key facts CIK 1448431 CUSIP 68401U204 13F (30d) 3 filings 3 filers Visit website Investor relations